Drug intelligence / Profile preview

SRx-T002

Development stage: Unknown
Lead developer: Sania Therapeutics
Modality: Gene Therapies
Administration: Intramuscular

Overview

SRx-T002 is a gene therapy under development by Sania Therapeutics for the treatment of neurological disorders, with a primary focus on muscle spasticity. The therapy is administered via intramuscular injection and is being investigated for use in nervous system diseases as well as skin and musculoskeletal diseases. As of the latest updates, its highest development phase is Discovery, indicating preclinical or very early-stage research. Detailed information about its mechanism of action or specific molecular targets has not been disclosed.

Other names: SRx T002

Beyond the preview

Go deeper on SRx-T002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRx-T002.

Explore the full profile